Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.65 |
| ▸ | ADA | P00813 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22224923 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL23761057 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL21136193 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL30303115 | 0.90 | ADORA2A (0.61) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL24939919 | 0.90 | ADORA2A (0.61) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL24082120 | 0.90 | ADORA2A (0.61) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL21136927 | 0.90 | ADORA2A (0.61) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL19953081 | 0.90 | ADORA2A (0.61) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL18041236 | 0.89 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL18061793 | 0.89 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2691409-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2552203-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9243025-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140163216-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8680071-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2691409-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2552203-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012154321-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011123586-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | SURLERAUX DOMINIQUE | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | ADORA2A 608/4885ADA 154/4885ADORA3 830/4885 |
| US-20140163216-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | ADORA2A 608/4885ADA 154/4885ADORA3 830/4885 |
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | ADORA2A 608/4885ADA 154/4885ADORA3 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.